StageZero Life Sciences Ltd.
SZLSFOTCHealthcare● Active
$0.01
+$0.00(+0.00%)
Market Cap$630018
P/E Ratio—
52W High$0.03109
52W Low$0.0005
StageZero Life Sciences Ltd. (SZLSF) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SZLSF · as of 2026-06-15
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($11.42M) | ($7.48M) | ($6.86M) | ($3.48M) | ($3.94M) |
| Depreciation & Amort. | $0.44M | $0.51M | $0.22M | $0.30M | $0.31M |
| Stock-Based Comp. | $0.24M | $0.39M | $0.64M | $0.74M | $0.43M |
| Change in Working Capital | $3.71M | ($0.46M) | ($0.08M) | ($0.38M) | $0.34M |
| Net Cash from Operations | ($3.53M) | ($8.95M) | ($3.06M) | ($4.59M) | ($3.29M) |
| Investing Activities | |||||
| Capital Expenditure | $0.00M | ($0.15M) | ($0.07M) | ($0.04M) | ($0.00M) |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | $0.00M | ($0.02M) | ($0.07M) | ($0.03M) | ($0.00M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.29M | ($0.39M) | $0.52M | $0.65M | $1.39M |
| Net Cash from Financing | $1.83M | $4.10M | $9.66M | $4.59M | $3.36M |
| Free Cash Flow | |||||
| Free Cash Flow | ($3.53M) | ($9.10M) | ($3.14M) | ($4.64M) | ($3.29M) |
| FCF Margin %(computed) | -92.98% | -179.61% | -75.55% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-15 · USD · M
Explore more StageZero Life Sciences Ltd. data
About StageZero Life Sciences Ltd. (SZLSF) Cash Flow Statement
StageZero Life Sciences Ltd. generated operating cash flow of ($0.00B) and free cash flow of ($0.00B) for 2022 — a FCF margin of -92.98%. Capital expenditure was $0.00B.
Frequently asked questions
SZLSF · 4 questionsStageZero Life Sciences Ltd. generated free cash flow of ($0.00B) for 2022, up 61.2% year-over-year.
SZLSF free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-15